SUPPLEMENTARY MATERIAL

Contents

*Definition of rapid correction of hyponatremia used in the reanalysis*

**Supplementary Table S1.** Summary of thresholds used to define rapid correction of hyponatremia and the extrapolation used for measures between defined timelines

*Patient disposition*

**Supplementary Table S2.** Patient disposition and reasons for discontinuation

*Serum sodium over time*

**Supplementary Figure S1.** Mean (SD) serum sodium (mmol/L) in patients grouped by stable daily tolvaptan dose received

*Treatment-emergent adverse events by concomitant medication use and timing of event in relation to concomitant medication use*

**Supplementary Table S3.** Patients with treatment-emergent adverse events by prior or concomitant use of cytochrome P450 3A4 inhibitors (system organ classes with ≥10% of patients of any subgroup reporting an event in the system organ class are shown)

**Supplementary Table S4.** Patients with treatment-emergent adverse events by prior or concomitant use of cytochrome P450 3A4 inducers (system organ classes with ≥10% of patients of any subgroup reporting an event in the system organ class are shown)

**Supplementary Table S5.** Patients with treatment-emergent adverse events by prior or concomitant use of serum potassium concentration increasing substances (system organ classes with ≥10% of patients of any subgroup reporting an event in the system organ class are shown)

**Supplementary Table S6.** Patients with treatment-emergent adverse events by prior or concomitant use of either warfarin or antiplatelet agents (system organ classes with ≥10% of patients of any subgroup reporting an event in the system organ class are shown)
Definition of rapid correction of hyponatremia used in the reanalysis

- Too rapid correction of hyponatremia (serum sodium increase ≥ 12 mmol/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriplegia, seizures, coma, or death. Therefore, after initiation of tolvaptan, patients should be closely monitored for serum sodium and volume status.

- Due to these risks, more precautionary limits to the rise of serum sodium apply in the early treatment phase. If sodium correction exceeds 6 mmol/L during the first 6 hours of administration or 8 mmol/L during the first 6-12 hours, respectively, the possibility that serum sodium correction may be overly rapid should be considered. These patients should be monitored more frequently regarding their serum sodium and administration of hypotonic fluid is recommended. In case serum sodium increases ≥12 mmol/L within 24 hours or ≥18 mmol/L within 48 hours, tolvaptan treatment is to be interrupted or discontinued followed by administration of hypotonic fluid.

Differences in serum sodium of 4 mmol/L or less if they occurred within 4 hours or less were not taken into account.

Supplemental Table S1. Summary of thresholds used to define rapid correction of hyponatremia and the extrapolation used for measures between defined timelines

| Threshold for serum sodium increase from SmPC | Time interval between 2 tests (hours) | Extrapolation used for time interval between defined values |
|---------------------------------------------|-------------------------------------|-----------------------------------------------------------|
| 6 mmol/L at 6 hours                         | 4 < T < 6 hours                     | Na/T ≥ 1                                                   |
| 8 mmol/L at 12 hours                        | 6 ≤ T < 24 hours                    | Na/([T/3] + 4) ≥ 1                                        |
| 12 mmol/L at 24 hours                       | 6 ≤ T < 24 hours                    |                                                           |
| 18 mmol/L at 48 hours                       | 24 ≤ T ≤ 72 hours                   | Na/([T/4] + 6) ≥ 1                                        |

Na, sodium; SmPC, Summary of Product Characteristics; T, time in hours between the predose and postdose tests.
Patient disposition

Supplemental Table S2. Patient disposition and reasons for discontinuation

| n (%) | Population (N=252) |
|-------|---------------------|
| Total number of enrollment periods | 271 |
| Patients with >1 enrollment period | 18 |
| Completed treatment* | 41 (15.1) |
| Discontinued treatment | 176 (64.9) |
| Lack of efficacy | 5 (1.8) |
| Adverse event | 5 (1.8) |
| Patient withdrew consent | 3 (1.1) |
| Patient lost to follow-up | 31 (11.4) |
| Patient passed away | 47 (17.3) |
| Discretion of the investigator | 21 (7.7) |
| Other | 64 (23.6) |
| Condition resolved* | 3 (1.1) |
| Discretion of the patient | 1 (0.4) |
| Disease progression | 5 (18.0) |
| General practitioner decision | 7 (2.6) |
| Lack of follow-up | 2 (0.7) |
| N/A study completed | 1 (0.4) |
| Non-compliance | 2 (0.7) |
| Other | 5 (1.8) |
| Other treatment | 1 (0.4) |
| Other: N/A | 1 (0.4) |
| Physician decision | 5 (1.8) |
| Physician decision (discretion of other physician) | 1 (0.4) |
| Serum sodium normalized* | 16 (5.9) |
| Unknown | 14 (5.2) |

*The category “Completed treatment” in principle includes states of “Condition resolved” and “Serum sodium normalized.” In some cases, however, the reporter entered corresponding free text, which is the reason for the presence of the categories “Condition resolved” and “Serum sodium normalized” in this table.
**Serum sodium over time**

**Supplemental Figure S1.** Mean (SD) serum sodium (mmol/L) in patients grouped by stable daily tolvaptan dose received.

Patients who did not enter a stable treatment phase were grouped according to their most used dose. Data are not shown for patients who received tolvaptan 45 mg/day (n=1) or 60 mg/day (n=1) as a stable dose, given the small number of patients in each treatment group.

BSL, baseline; D, day; M, month; SD, standard deviation; W, week.
**Treatment-emergent adverse events by concomitant medication use and timing of event in relation to concomitant medication use**

**Supplemental Table S3.** Patients with treatment-emergent adverse events by prior or concomitant use of cytochrome P450 3A4 inhibitors (system organ classes with ≥10% of patients of any subgroup reporting an event in the system organ class are shown)

| Patient s with any adverse events | N=98  | N=154 |
|----------------------------------|-------|-------|
| Blood and lymphatic system disorders | n=72  | n=43  | n=93  |
| Gastrointestinal disorders | 12 (12.2%) | 8 (8.2%) | 5 (3.2%) |
| General disorders and administration site conditions | 26 (26.5%) | 20 (20.4%) | 25 (16.2%) |
| Infections and infestations | 21 (21.4%) | 15 (15.3%) | 24 (15.6%) |
| Investigations | 24 (24.5%) | 15 (15.3%) | 19 (12.3%) |
| Metabolism and nutrition disorders | 14 (14.3%) | 12 (12.2%) | 9 (5.8%) |
| Musculoskeletal and connective tissue disorders | 12 (12.2%) | 6 (6.1%) | 1 (0.6%) |
| Neoplasms benign, malignant, and unspecified (incl cysts and polyps) | 11 (11.2%) | 10 (10.2%) | 22 (14.3%) |
| Nervous system disorders | 10 (10.2%) | 7 (7.1%) | 16 (10.4%) |
| Psychiatric disorders | 12 (12.2%) | 15 (15.3%) | 15 (9.7%) |
| Respiratory, thoracic, and mediastinal disorders | 17 (17.3%) | 15 (15.3%) | 13 (8.4%) |
| Surgical and medical procedures | 13 (13.3%) | 6 (6.1%) | 31 (20.1%) |

CYP3A4, cytochrome P450 3A4 inhibitor; TEAE, treatment-emergent adverse event.
**Supplemental Table S4.** Patients with treatment-emergent adverse events by prior or concomitant use of cytochrome P450 3A4 inducers (system organ classes with ≥10% of patients of any subgroup reporting an event in the system organ class are shown)

| System Organ Class                                      | TEAEs With CYP3A4 Administration [N=59] | TEAEs Without CYP3A4 Administration [N=193] |
|--------------------------------------------------------|-----------------------------------------|---------------------------------------------|
| Patients with any adverse events                       | n=34                                    | n=126                                       |
| Blood and lymphatic system disorders                   | 5 (8.5%)                                | 12 (6.2%)                                  |
| Gastrointestinal disorders                             | 16 (27.1%)                              | 40 (20.7%)                                 |
| General disorders and administration site conditions   | 15 (25.4%)                              | 34 (17.6%)                                 |
| Infections and infestations                            | 10 (16.9%)                              | 36 (18.7%)                                 |
| Investigations                                         | 9 (15.3%)                               | 18 (9.3%)                                  |
| Metabolism and nutrition disorders                     | 13 (22.0%)                              | 26 (13.5%)                                 |
| Neoplasms benign, malignant, and unspecified (incl cysts and polyps) | 5 (8.5%)                                | 24 (12.4%)                                 |
| Nervous system disorders                               | 12 (20.3%)                              | 16 (8.3%)                                  |
| Psychiatric disorders                                  | 9 (15.3%)                               | 24 (12.4%)                                 |
| Respiratory, thoracic, and mediastinal disorders       | 10 (16.9%)                              | 25 (13.0%)                                 |
| Surgical and medical procedures                        | 12 (20.3%)                              | 33 (17.1%)                                 |

CYP3A4, cytochrome P450 3A4 inducer; TEAE, treatment-emergent adverse event.
**Supplemental Table S5.** Patients with treatment-emergent adverse events by prior or concomitant use of serum potassium concentration increasing substances (system organ classes with ≥10% of patients of any subgroup reporting an event in the system organ class are shown)

|                  | TEAEs With Serum Potassium Concentration Increasing Substances [N=43] | TEAEs Without Serum Potassium Concentration Increasing Substances [N=209] |
|------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|
|                  | TEAEs During Concomitant Use                                           | TEAEs Not During Concomitant Use                                         |
| Patients with any adverse events n=24 | n=27                                                                  | n=139                                                                    |
| Blood and lymphatic system disorders | 3 (7.0%)                                                               | 6 (14.0%)                                                               | 15 (7.2%) |
| Cardiac disorders | 0 (0.0%)                                                               | 9 (20.9%)                                                               | 9 (4.3%) |
| Gastrointestinal disorders | 9 (20.9%)                                                             | 13 (30.2%)                                                              | 45 (21.5%) |
| General disorders and administration site conditions | 9 (20.9%)                                                             | 12 (27.9%)                                                              | 37 (17.7%) |
| Infections and infestations | 8 (18.6%)                                                             | 12 (27.9%)                                                              | 36 (16.7%) |
| Injury, poisoning, and procedural complications | 0 (0.0%)                                                             | 5 (11.6%)                                                               | 8 (3.8%) |
| Investigations | 5 (11.6%)                                                              | 5 (11.6%)                                                               | 20 (10.0%) |
| Metabolism and nutrition disorders | 9 (20.9%)                                                             | 9 (20.9%)                                                               | 28 (13.4%) |
| Musculoskeletal and connective tissue disorders | 2 (4.7%)                                                              | 6 (14.0%)                                                               | 11 (5.3%) |
| Neoplasms benign, malignant, and unspecified (incl cysts and polyps) | 3 (7.0%)                                                             | 11 (25.6%)                                                              | 28 (13.4%) |
| Nervous system disorders | 3 (7.0%)                                                             | 6 (14.0%)                                                               | 24 (11.5%) |
| Psychiatric disorders | 3 (7.0%)                                                              | 8 (18.6%)                                                               | 30 (14.4%) |
| Respiratory, thoracic, and mediastinal disorders | 3 (7.0%)                                                             | 7 (16.3%)                                                               | 31 (14.8%) |
| Surgical and medical procedures | 3 (7.0%)                                                             | 5 (11.6%)                                                               | 41 (19.6%) |
| Vascular disorders | 3 (7.0%)                                                              | 7 (16.3%)                                                               | 16 (7.7%) |

TEAE, treatment-emergent adverse event.
Supplemental Table S6. Patients with treatment-emergent adverse events by prior or concomitant use of either warfarin or antiplatelet agents (system organ classes with $\geq 10\%$ of patients of any subgroup reporting an event in the system organ class are shown)

| Patient Subgroup | TEAEs With Either Warfarin or Antiplatelet Agents [N=83] | TEAEs Without Either Warfarin or Antiplatelet Agents [N=169] |
|------------------|----------------------------------------------------------|-------------------------------------------------------------|
|                   | TEAEs During Concomitant Use | TEAEs Not During Concomitant Use |                             |
| Patients with any adverse events | n=49 | n=28 | n=115 |
| Gastrointestinal disorders | 16 (19.3%) | 9 (10.8%) | 42 (24.9%) |
| General disorders and administration site conditions | 21 (25.3%) | 8 (9.6%) | 31 (18.3%) |
| Infections and infestations | 18 (21.7%) | 8 (9.6%) | 32 (18.9%) |
| Investigations | 11 (13.3%) | 4 (4.8%) | 17 (10.1%) |
| Metabolism and nutrition disorders | 17 (20.5%) | 5 (6.0%) | 22 (13.0%) |
| Neoplasms benign, malignant, and unspecified (incl cysts and polyps) | 8 (9.6%) | 5 (6.0%) | 28 (16.6%) |
| Nervous system disorders | 12 (14.5%) | 3 (3.6%) | 18 (10.7%) |
| Psychiatric disorders | 15 (18.1%) | 5 (6.0%) | 21 (12.4%) |
| Respiratory, thoracic, and mediastinal disorders | 15 (18.1%) | 6 (7.2%) | 22 (13.0%) |
| Surgical and medical procedures | 8 (9.6%) | 2 (2.4%) | 38 (22.5%) |
| Vascular disorders | 10 (12.0%) | 4 (4.8%) | 12 (7.1%) |

TEAE, treatment-emergent adverse event.
List of study investigators

Denmark
Prof. Feldt-Rasmussen, Copenhagen; Dr. Trolle, Aarhus; Dr. Rittig, Aarhus; Prof. Pedersen, Holstebro

Germany
Prof. Fassnacht, Würzburg; Dr. Renders, Kiel; Dr. Haas, Lübeck; Dr. Gaedeke, Berlin; Dr. Burst, Köln; Dr. Hensen, Hannover; Dr. Karges, Aachen; Dr. Feldkamp, Essen; Dr. Aberle, Hamburg; Dr. Obermüller, Frankfurt; Prof. Hugo, Dresden; Prof. Manegold, Mannheim; Prof. Willenberg, Düsseldorf; Prof. Hampel/Dr. Knauerhase; Rostock; Dr. Terkamp, Hannover; Dr. Rudofsky, Heidelberg; Dr. Schäffler, Regensburg; Prof. Hausberg, Karlsruhe; Dr. Bischoff, Heidelberg

Italy
Dr. Boretta, Cuneo; Dr. Zei, Siena; Dr. Capasso, Naples; Prof. Peri, Firenze

Norway
Prof. Omland/Dr. Winther, Lorenskog

Spain
Dr. Landecho, Pamplona; Dr. Serrano, Alicante; Dr. Garcia Donaire, Madrid; Dr. Boceta Osuna, Sevilla; Dr. Toledo Rojas, Malaga; Dr. Casanueva, Sant. de Compostela; Dr. Hernandez Jaras, Valencia; Dr. Aramburu Bodas, Sevilla; Dr. Runkle, Madrid; Dr. Velilla, Zaragoza; Dr. Guerrero Pabón, Córdoba; Dr. Aller, Majadahonda; Dr. Radiu, Castellon; Dr. De las Peñas, Castellon

Sweden
Dr. Hoeybye, Stockholm; Prof. Johannsson, Göteborg; Dr. Ekmann, Linköping; Dr. Jendle, Karlstad

United Kingdom
Dr. Nasruddin, Southampton; Dr. Andrews, Taunton; Dr. Jude, Oldham; Dr. Cuthbertson, Liverpool; Dr. Cross, Plymouth; Dr. Solomon, Preston; Dr. Selby, Manchester Royal Infirmary; Dr. Younis, Wythenshawe Hospital Manchester; Dr. Weickert, Coventry; Dr. Shakher, Birmingham Heartlands; Dr. Saravannan, Nuneaton; Dr. Oldfield, Kingston-Upon-Thames; Prof. Brabant/Prof. Trainer, Manchester; Dr. Purewal, Liverpool; Dr. Anthony, Hartlepool; Dr. Abougliila, Durham; Dr. Savage, Manchester; Dr. Bhatnagar, Oldham; Dr. Ulahanan, Gloucester